albuterol (Armstrong Albuterol HFA) vs Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline

albuterol (Armstrong Albuterol HFA)

Marketed by Amphastar Pharmaceuticals, Inc.

Approved in Asthmasmall molecule
Partial signal

NCT00634829 · Phase 3 · terminated

This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Next expected readout: April 2028 · NCT07426458 (registry estimate)

No aligned efficacy figure on record for this race.

Vilanterol

Developed by GlaxoSmithKline

Phase 3 in Asthmasmall molecule
Partial signal

NCT00381667 · Phase 2 · completed

The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.

Reported efficacy

Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)

Result source: NCT00600171

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointalbuterol (Armstrong Albuterol HFA)Vilanterol
Severe exacerbations, annualised rate—Not posted · NCT00667407—Not reported
Trough FEV1, change—Not posted · NCT006674070.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Not posted · NCT00667407—Not reported
OCS dose reduction—Not posted · NCT00667407—Not reported

Severe exacerbations, annualised rate

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Vilanterol
—Not reported

Trough FEV1, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Vilanterol
0.3 vs 0.1+0.1 vs placebo25 µg · wk 4 · n 99NCT00600171
8 other results
  • 0.3 vs 0.1 50 µg · wk 4 · n 100 · Phase 2 · primary NCT00600171
  • 0.3 vs 0.1 12.5 µg · wk 4 · n 97 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 6.25 µg · wk 4 · n 99 · Phase 2 · primary NCT00600171
  • 0.2 vs 0.1 3 µg · wk 4 · n 98 · Phase 2 · primary NCT00600171
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Vilanterol
—Not reported

OCS dose reduction

albuterol (Armstrong Albuterol HFA)
—Not posted · NCT00667407
Vilanterol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. albuterol (Armstrong Albuterol HFA): 0 of 4 rows · Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVilanterol
Dropout rate
7.9%25 µga
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
4.9%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
9.9%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
16.8%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.2%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1%25 µga
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
1%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Serious AEs
0%25 µga
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 16 more results
0%50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0%3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.9%25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%100/25 µg AM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%25 µg
NCT01453296 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
25 µga
headache 6.9% (placebo 7.8%)
upper respiratory tract infection 2% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 13 more results
50 µg
headache 7.8% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
12.5 µg
headache 9% (placebo 7.8%)
upper respiratory tract infection 3% (placebo 2%)
nasopharyngitis 0% (placebo 3.9%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
6.25 µg
headache 6.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 1% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
3 µg
headache 11.9% (placebo 7.8%)
nasopharyngitis 2% (placebo 3.9%)
upper respiratory tract infection 2% (placebo 2%)
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25 µg OD
headache 8.7% (placebo 4.3%)
nasopharyngitis 7.8% (placebo 10.3%)
oropharyngeal pain 5.2% (placebo 6%)
NCT01181895 · Phase 3 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
100/25 µg AM
headache 25% (placebo 26.1%)
nasopharyngitis 12.5% (placebo 13%)
dysmenorrhoea 4.2% (placebo 0%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg PM
headache 32% (placebo 26.1%)
gastroenteritis 8% (placebo 0%)
nasopharyngitis 8% (placebo 13%)
NCT01287065 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
25 µg
upper respiratory tract infection 11.1% (placebo 0%)
headache 7.4% (placebo 7.7%)
pyrexia 7.4% (placebo 0%)
NCT01453296 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Vilanterol

FEV1 Trough -0.478 vs -0.809 placebo L @ 4.14wk100/25 µg OD
absolute change · L
NCT01128569 · Phase 2 · registry result, not featured evidence
show 8 more results
0.269 vs 0.147 placebo L @ 4wk25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.193 vs 0.223 placebo L @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.309 vs 0.147 placebo L @ 4wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.278 vs 0.147 placebo L @ 4wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.24 vs 0.223 placebo L @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.217 vs 0.147 placebo L @ 4wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.166 vs 0.223 placebo L @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.212 vs 0.147 placebo L @ 4wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
FEV1 AUC0-24 0.33 vs 0.137 placebo L @ 0.14wk25 µg
absolute change · L
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 9 more results
0.315 vs 0.149 placebo L @ 4wk25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.352 vs 0.137 placebo L @ 0.14wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.321 vs 0.149 placebo L @ 4wk50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.267 vs 0.137 placebo L @ 0.14wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.292 vs 0.149 placebo L @ 4wk12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.215 vs 0.137 placebo L @ 0.14wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.253 vs 0.149 placebo L @ 4wk6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.239 vs 0.137 placebo L @ 0.14wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
0.3 vs 0.149 placebo L @ 4wk3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Evening PEF 34 vs 0.4 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
24.9 vs 11 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
38.4 vs 0.4 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
28.9 vs 0.4 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
24.5 vs 0.4 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
14 vs 0.4 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Morning PEF 38.1 vs 1.9 placebo L/min25 µg
absolute change · L/min
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 5 more results
28 vs 14.2 placebo L/min @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
44 vs 1.9 placebo L/min50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
34.2 vs 1.9 placebo L/min12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8 vs 1.9 placebo L/min6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
18.7 vs 1.9 placebo L/min3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Symptom-free 24 h Periods 36.4% (n=101) vs 14.2% (n=98) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
32.3% (n=102) vs 14.2% (n=98) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
26.8% (n=98) vs 14.2% (n=98) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
23.6% (n=101) vs 14.2% (n=98) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
22.6% (n=99) vs 14.2% (n=98) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
Rescue-free 24 h Periods 43.4% (n=101) vs 15% (n=99) placebo25 µg
absolute change · percentage points
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
show 4 more results
34% (n=102) vs 15% (n=99) placebo50 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
29.6% (n=98) vs 15% (n=99) placebo12.5 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
27.3% (n=101) vs 15% (n=99) placebo6.25 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
25.8% (n=99) vs 15% (n=99) placebo3 µg
NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2
FEV1 Wm0 24 h 3.188 vs 2.811 placebo L @ 2wk100/25 µg AM
absolute change · L
NCT01287065 · Phase 2 · registry result, not featured evidence
show 2 more results
3.233 vs 2.811 placebo L @ 2wk100/25 µg PM
NCT01287065 · Phase 2 · registry result, not featured evidence
0.359 vs 0.289 placebo L @ 12wk25 µg OD
NCT01181895 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period 21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg OD
percent change · % of baseline
NCT01181895 · Phase 3 · registry result, not featured evidence
show 3 more results
2.98% (n=110) vs 14.4% (n=113) placebo @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
15.8% (n=112) vs 14.4% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.2% (n=113) vs 14.4% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Symptom-free 24-h Period 19.4% (n=115) vs 12.7% (n=115) placebo @ 12wk25 µg OD
percent change · % of baseline
NCT01181895 · Phase 3 · registry result, not featured evidence
show 3 more results
19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
FEV1 0.33 vs 0.301 placebo L @ 12wk25 µg OD
absolute change · L
24 hours, n= 95, 101, 100
NCT01181895 · Phase 3 · registry result, not featured evidence
Evening PEF Change L/Min 220.3 vs 215.9 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
11.1 vs 5.9 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
222.4 vs 215.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.7 vs 5.9 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
221.4 vs 215.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
9.4 vs 5.9 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
absolute change · L/min
NCT01573767 · Phase 2 · registry result, not featured evidence
show 5 more results
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · Vilanterol's landscape